Deputy Nguyễn Lân Hiếu, director of Bệnh viện Đại học Y Hà Nội, proposed allowing hospitals to use patents and trademarks as capital contributions or loan collateral to strengthen their autonomy. Speaking during the National Assembly's debate on the amended Law on Intellectual Property on November 3, he proposed that changes such as new salt forms, formulations or dosages of known substances not be considered inventive unless they significantly improve treatment efficacy. He also proposed that domestic firms be allowed to file generic drug registrations while the original patent is still valid, as otherwise they could wait 2-3 years after the patent expires before selling. On AI and copyright, he proposed that AI cannot be an author, that doctors and lecturers be authors while hospitals and universities own the rights when state budgets are used, with at least 40-50% of profits shared with authors. Deputy Nguyễn Trung Kiên of Đồng Nai agreed and urged digital platforms to handle copyright infringement notices and promptly remove or block infringing content, noting that blocked sites often reappear under new domains.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Đề xuất cho phép bệnh viện dùng bằng sáng chế làm tài sản thế chấp vay vốn
Keywords
intellectual propertypatentspharmaceuticalsartificial intelligenceVietnam
Open a keyword to see other news on the same topic.
Related tickers and likely impact
VNINDEX
• NeutralRelevance: low
| Market | Vietnam stocks |
|---|---|
| Close on 11/02/2026 | 1,710.72 |
| Change that session | -1.77% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Many drugmakers extend patent monopolies, risking delays for cheaper medicines reaching patients
Deputy Nguyen Lan Hieu, director of Hanoi Medical University Hospital, told the National Assembly on 3 November that many drugmakers only change salt forms, formulations or dosages to win new patents and extend exclusivity beyond the usual protection period of about 20 years. This “evergreening” can delay cheaper generics reaching patients, so he proposed that changes without a significant improvement in treatment efficacy not be deemed inventive. He also proposed that Vietnamese firms be allowed to research, test and file for generic registration while the original patent remains in force, as otherwise they could wait 2–3 years before selling. On AI, he suggested that products created by AI without meaningful human creative input not receive copyright protection, and warned that Vietnamese medicinal plants could be taken abroad, patented and returned to the domestic market.
- Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
Pfizer (PFE) shares are up 20% year to date as the company emerges from its post-pandemic slump, though the article says the recovery is still at an early stage. Last quarter, revenue rose 3% and beat Wall Street expectations, helped by Eliquis and cancer drugs that offset lower COVID-19 product sales. Pfizer raised its full-year revenue guidance, reiterated adjusted EPS of $2.80 to $3 per share, and sees up to $6.7 billion in cost savings through 2029. The stock trades at about 10 times estimated 2026 earnings, while sell-side forecasts see 2027 EPS slipping from $2.96 to $2.88. Risks include clinical trial setbacks and the looming loss of patent protection for Eliquis and Ibrance.
- Why Merck Stock Flew Higher on Friday
Merck (MRK) shares climbed more than 2% on Friday, extending the positive reaction to its third-quarter results posted Thursday, while the S&P 500 fell a relatively steep 1.8%. Sales rose 5% to over $18 billion, driven by Keytruda, and non-GAAP net income fell 4% to nearly $6.2 billion, with both figures and its full-year 2026 guidance beating average analyst estimates. Two of the four big banks raised their price targets: Bank of America Securities to $165 from $163 and J.P. Morgan to $175 from $165, and both maintained their buy ratings. The author notes that Keytruda is approaching its patent cliff, but the pipeline offers room for another blockbuster, and the stock currently yields 2.3%.
- A pharma giant is moving past one patent cliff — but another is already looming
Novartis says remibrutinib, its experimental multiple sclerosis (MS) drug, could generate more than $4 billion in peak annual sales, even though Barclays recently cut its peak sales forecast after late-stage trials showed it reduced relapses by less than analysts expected. The drug belongs to the BTK inhibitor class and aims to regulate immune cell activity rather than eliminate cells, unlike Kesimpta, an anti-CD20 antibody. University of Pennsylvania MS specialist Amit Bar-Or said its safety profile looks promising but it is unlikely to control relapses as effectively as Kesimpta, and its biggest market-expansion opportunity could come from trials in progressive MS, with a readout expected in 2031. Morningstar analyst Jay Lee said the $4 billion-plus forecast is 'within the realm of possibility' but not de-risked. Meanwhile, the market is already looking to the next patent cliff around 2032 for Kisqali and Kesimpta, whose expiries alone represent $18 billion in peak sales.
- Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers Squibb's Growth Portfolio rose 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion, while shares were roughly flat in midday trading. Adjusted EPS fell 17% to $1.35 from $1.63, mainly because of acquired IPRD charges for upfront payments on licensed drug candidates, which cost $0.58 a share net of licensing income. The Legacy Portfolio rose 1%, helped by Eliquis outpacing generic erosion, though Eliquis faces patent expiration later this decade. The company raised its 2026 revenue guidance to $49.75 billion to $50.25 billion, and the adjusted EPS range was updated to absorb the charges. The article says investors should watch whether the Growth Portfolio holds double-digit growth and whether the licensed programs produce data that justifies their cost.
- Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Pfizer declared a $0.43 fourth-quarter dividend, its 352nd consecutive quarterly payout, which annualizes to $1.72 per share and a 5.9% yield, well above the roughly 1% average S&P 500 yield. The article asks whether the payout is sustainable, noting Pfizer halved its dividend in 2009 but has raised it every year since 2010. Eliquis and Xeljanz lose U.S. patent exclusivity this year, and Ibrance and Xtandi follow next year, which pressures revenue. Nurtec grew 18% in the second quarter, Lorbrena 37% and Padcev 23%, and free cash flow of about $11 billion over four quarters exceeded dividend payments by more than $1 billion. The author concludes that the dividend's durability depends on whether new pipeline drugs can replace the expiring ones.
Related markets
Latest news
- NVDA Shares Inch Higher Overnight After 4-Day Rout: Chipmaker Reportedly Tells Cloud Clients To Limit China Exposure
Nvidia (NVDA) shares rose 0.8% in overnight trading after a four-session slide. The Financial Times reported that Nvidia has told its cloud computing clients to scale back exposure to Chinese companies, requiring at least 51% of their services to be sold to customers outside China, though the rules apply only to future contracts. An Nvidia spokesman said America's AI infrastructure must win worldwide. Separately, Marvell (MRVL) agreed to buy Lumentum (LITE) in an all-stock deal valuing it at an implied enterprise value of $115 billion, and Nvidia had invested $2 billion in each company earlier this year. Nvidia reports third-quarter results on Nov. 17, while investors await AMD's quarterly report after the close on Tuesday.
- FTSE 100 falls amid global tech rout, looming U.S. mid-terms and BoE
The FTSE 100 fell 0.4% on Tuesday, snapping a four-session winning streak, as Associated British Foods (ABF) shares dropped 3%. ABF reported adjusted operating profit of £1.508 billion for the fiscal year ended September 12, 2026, down 14% year on year, hit by weak consumer spending at Primark and a sharp slump in European sugar prices. Broader sentiment was also weighed by Apple's warning that memory chip costs would compress gross margins and Oracle's plan to raise $20 billion for AI and cloud infrastructure. Investors also remained cautious ahead of U.S. midterm elections, with all 435 House seats and 35 Senate seats contested, and the Bank of England's rate decision later this week.
- Foreign investors dump nearly 500 billion dong of two bank stocks in the Nov. 3 session
Foreign investors net sold about 496 billion dong of stocks across the market in the Nov. 3 session, as the VN-Index fell 11 points to 1,699 with HoSE trading value near 13,000 billion dong. On HoSE, foreigners net sold 500 billion dong, led by bank stocks MBB (254 billion dong) and VCB (219 billion dong), and VIC (114 billion dong). HPG was the top net-bought stock on HoSE at over 227 billion dong, followed by SHB and VHM at 125 billion and 119 billion dong. On HNX, foreigners net bought 7 billion dong, led by MBS, while on UPCOM they net sold 2.5 billion dong. Market sentiment remained cautious, with the index swinging sharply during the session.
- European shares slide as Apple margin warning trigger global tech rout
The pan-European STOXX 600 fell 0.7% on Tuesday, with Germany's DAX down nearly 1% and France's CAC 40 down 0.5%, as a global tech sell-off spread. Apple's warning that rising memory chip prices would squeeze gross margins through the holiday quarter hit European chip stocks, with ASML, ASM International and BE Semiconductor down 2% to 4% and STMicroelectronics and Infineon each down over 3%. Oracle's plan to raise $20 billion for cloud and AI infrastructure added to worries over tech spending. Koninklijke Philips rose 6.4% after higher quarterly profit, while Lufthansa gained 1.6% despite narrowing its full-year 2026 operating profit forecast due to soaring jet fuel costs.
- The Qeshm strike and the risk of escalating airstrikes: What is Trump calculating on Iran and the midterm elections?
The U.S. strike on Qeshm island on the night of Nov. 2 is described as a controlled response to Iran firing on a U.S. aircraft, rather than the start of a broader campaign. According to The Atlantic, the White House has discussed scenarios ranging from strikes lasting a few hours to multi-week campaigns, with any major escalation seen as more likely once the midterm results are clear. Trump is reportedly seeking to use limited military pressure to bring Iran back to the negotiating table, while rising gasoline prices and living costs weigh on voters. A Reuters/Ipsos poll found about 60% of Americans, including some Republicans, do not approve of how Trump is handling Iran. Supreme Leader Mojtaba Khamenei has ordered the armed forces to be ready to respond if the conflict resumes.
- Brookfield targets $27 billion AI data center at power station. Energy firm Drax surges 8%
Brookfield is targeting a large AI data center in northern England, as Europe races to build infrastructure for AI amid high energy and land costs. Drax Group said it signed an agreement with Brookfield and its neocloud platform Radiant to jointly develop the facility on the Drax Power Station estate in North Yorkshire. The initial phase targets up to 100 MW of capacity from Q1 2028, with another 500 MW coming online between 2028 and 2031, and the project later aims to secure over 1 gigawatt at the site by an unspecified date. Brookfield estimates total investment, including semiconductors, could exceed £20 billion ($26.8 billion), with an initial £2.5 billion in phase 1. Drax shares rose 8.2% in early trading in London.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.